Micafungine Viatris

Micafungin, the active ingredient in Micafungine Viatris, is an echinocandin presented as an intravenous solution for intravenous use. It is employed to treat serious Candida infections, including bloodstream and intra‑abdominal disease, and is used for prophylaxis in high‑risk transplant patients.

GNH USA supplies Micafungine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungine Viatris is an echinocandin antifungal indicated for several invasive Candida infections. - Candidemia: rapid clearance of Candida species from the bloodstream. - Intra‑abdominal infections (peritonitis, intra‑abdominal abscesses): eradication of Candida from the peritoneal cavity. - Esophageal candidiasis: resolution of mucosal lesions and symptom relief. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevention of invasive candidiasis in immunocompromised patients.

Micafungine Viatris may be associated with a range of adverse reactions.

Common Side Effects: - Elevated liver enzymes: transient increase in ALT or AST. - Fever: mild to moderate temperature rise. - Nausea: occasional gastrointestinal discomfort. - Headache: mild, self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Infusion‑related reactions: hypotension or bronchospasm. - Renal impairment: rare acute kidney injury.

Before initiating Micafungine Viatris, clinicians should consider several safety aspects. - Liver function: assess baseline enzymes and monitor during therapy. - Renal function: evaluate creatinine clearance, especially in patients with pre‑existing kidney disease. - Drug interactions: review concomitant medications that affect hepatic metabolism. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Pediatric use: safety and efficacy not established; reserve for specific indications. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine Viatris can interact with other agents that influence its metabolism or increase toxicity.

Major Interactions (Avoid): - Cyclosporine: may increase micafungin exposure, raising risk of hepatotoxicity. - Rifampin: can reduce micafungin plasma levels, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter hepatic enzyme activity; monitor liver tests. - Statins (e.g., simvastatin): potential for increased statin concentrations; assess for myopathy. - Immunosuppressants (e.g., tacrolimus): monitor drug levels due to possible pharmacokinetic changes.